High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology

Article information

Obstet Gynecol Sci. 2020;63(2):107-107
Publication date (electronic) : 2020 February 18
doi : https://doi.org/10.5468/ogs.2020.63.2.107
Tae-Wook Kong1, Miseon Kim2, Young-Han Kim3, Yong Beom Kim4, Jayeon Kim5, Jae-Weon Kim6, Mi Hye Park7, Joo Hyun Park8, Jeong Ho Rhee9, Myong Cheol Lim10, Joon-Seok Hong4, on behalf of Korean Society of Obstetrics and Gynecology developed by Position Statement Writing Committee
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
2Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea.
3Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
4Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
5Department of Obstetrics and Gynecology, CHA Seoul Fertility Center, CHA University School of Medicine, Seoul, Korea.
6Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
7Department of Obstetrics and Gynecology, College of Medicine, Ewha Womans University, Seoul, Korea.
8Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
9Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
10Department of Obstetrics and Gynecology, Cancer Healthcare Research Branch and Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Correspondence: Korean Society of Obstetrics and Gynecology. 4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea. office@ksog.org

Abstract

Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts:

• Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia.

• Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method.

• The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years.

• Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval.

Note

This statement states the official position of the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology and is published jointly in the Obstetrics & Gynecologic Science and the Journal of Gynecologic Oncology. It has no legal and or political validity for clinical decisions.

Supplementary associated with this article can be found online at https://doi.org/10.5468/ogs.2020.63.2.107.

Supplementary

Article information Continued